Literature DB >> 34318013

Commentary: Sometimes there is a simpler route!

Mevlüt Çelik1, Simon Maltais2.   

Abstract

Entities:  

Year:  2020        PMID: 34318013      PMCID: PMC8306201          DOI: 10.1016/j.xjtc.2020.08.062

Source DB:  PubMed          Journal:  JTCVS Tech        ISSN: 2666-2507


× No keyword cloud information.
Despite the perceived complexity, the route can be simpler. Left axillary–right axillary outflow tract grafting for left ventricular assist device implantation is feasible; simpler or more reproducible options should be considered for high-risk patients. See Article page 197. Left ventricular assist device (LVAD) implantation is an established treatment modality for patients with terminal heart failure. Correct positioning of the outflow-graft is one of the key factors for determining the long-term outcome of patients. Graft malposition can increase turbulence, effect pump performance, and increase subsequent risk of pump thrombosis or cerebrovascular complications., The main site of outflow graft placement, the ascending aorta, has been widely studied. Advancements in alternative implant strategies, combined with miniaturization of the technology, have broadened the strategy for outflow graft placement to major arteries such as the descending aorta, the innominate, the subclavian, or even the axillary artery.5, 6, 7, 8 In this issue of the Journal, Tucker and colleagues report the results of LVAD implantation with a novel alternative approach, the left axillary–right axillary arterial bypass (LARAAB) graft. In a minimally invasive setting, LARAAB was performed in a patient with a history of ischemic cardiomyopathy who underwent LVAD implantation for cardiogenic shock. The peculiarity of the described case lies in the fact that the previously placed outflow graft on the left axillary artery did not result in postoperative hemodynamic improvement whereas there was no notable anatomic obstruction. The patient required increasing vasopressor support caused by insufficient LVAD outflow and decision for reoperation was made. During reconstruction, the LVAD did not tolerate partial side clamping, and no anastomotic reconstruction on the graft itself could have been made, and this variant, LARAAB, was performed. The Latin proverb Aut viam inveniam aut faciam (“I shall either find a way or make one”) appropriately describes the authors' creative ability to tackle this case, and the authors further opt LARAAB to be a feasible treatment strategy in case of porcelain ascending aorta, unattainable descending aorta, and small calibre axillary artery. Although this creative strategy can potentially be of additive value in the armamentarium of the cardiothoracic surgeon, several issues can arise, and we question the need for such an extension of a previously described strategy. When do we stop and plan a standard sternotomy intervention, refer the patient for greater-risk heart transplantation, or simply do not offer the LVAD intervention? What is the long-term outcome of such a strategy? If this technique is applicable in specific patients, how should we determine the right patient for this strategy? New complications will occur, especially with 2 grafts. In the postoperative low-output setting, how would we preoperatively adequately identify the culprit in case of LARAAB? Little is known about optimal placement, metric, rheology of flow, and appropriate dimensions of the graft for optimal postoperative hemodynamic results. The availability of multiple alternative surgical techniques in the armamentarium of the surgeon requires careful tailoring to the need of the patient. While the presented LARAAB intervention was performed with success, we caution our surgical community to start widely applying this technique and to look for other options. Sometimes there is a simpler route to help the cat get some milk.
  9 in total

Review 1.  Minimally invasive is the future of left ventricular assist device implantation.

Authors:  George Makdisi; I-Wen Wang
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

2.  Effect of cannula position in the thoracic aorta with continuous left ventricular support: four-dimensional flow-sensitive magnetic resonance imaging in an in vitro model.

Authors:  Christoph Benk; Alexander Mauch; Friedhelm Beyersdorf; Rolf Klemm; Maximilian Russe; Philipp Blanke; Jan G Korvink; Michael Markl; Bernd Jung
Journal:  Eur J Cardiothorac Surg       Date:  2013-02-28       Impact factor: 4.191

3.  Increase in left ventricular assist device thrombosis.

Authors:  Jan D Schmitto; Murat Avsar; Axel Haverich
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

4.  Temporary left ventricular assist device through an axillary access is a promising approach to improve outcomes in refractory cardiogenic shock patients.

Authors:  Karen M Doersch; Carl W Tong; Enrique Gongora; Subbareddy Konda; Basar Sareyyupoglu
Journal:  ASAIO J       Date:  2015 May-Jun       Impact factor: 2.872

5.  Left ventricular assist device outflow graft: alternative sites.

Authors:  Magdy M El-Sayed Ahmed; Muhammad Aftab; Steve K Singh; Hari R Mallidi; Oscar H Frazier
Journal:  Ann Cardiothorac Surg       Date:  2014-09

6.  LVAD Outflow Graft Angle and Thrombosis Risk.

Authors:  Alberto Aliseda; Venkat Keshav Chivukula; Patrick Mcgah; Anthony R Prisco; Jennifer A Beckman; Guilherme J M Garcia; Nahush A Mokadam; Claudius Mahr
Journal:  ASAIO J       Date:  2017 Jan/Feb       Impact factor: 2.872

7.  Minimally invasive and alternative approaches for long-term LVAD placement: the Vanderbilt strategy.

Authors:  Simon Maltais; Mary E Davis; Nicholas Haglund
Journal:  Ann Cardiothorac Surg       Date:  2014-11

8.  Principles of HeartMate II implantation to avoid pump malposition and migration.

Authors:  Robert M Adamson; Abeel A Mangi; Robert L Kormos; David J Farrar; Walter P Dembitsky
Journal:  J Card Surg       Date:  2014-12-04       Impact factor: 1.620

9.  Left ventricular assist device implantation with axillary-axillary outflow graft.

Authors:  Dominique L Tucker; John Perry; Ashley Bock; Aaron Douglas; Chonyang Albert; Lee Kirksey; Michael Zhen-Yu Tong
Journal:  JTCVS Tech       Date:  2020-08-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.